The National Institute for Health and Care Excellence (NICE) recommends relugolix-estradiol-norethisterone (relugolix combination therapy [CT]) (▼Ryeqo®) and linzagolix (▼Yselty®) as oral treatments for the following indications:
- Moderate-to-severe symptoms of uterine fibroids in adults of reproductive age [NICE TA832] [NICE TA996]
- Endometriosis in adults of reproductive age who have had medical or surgical treatment for endometriosis [NICE TA1057] [NICE TA1067]
These medications are classified as AMBER 2. This indicates that specialist initiation with maintenance in primary care: specialist involvement is required during initiation with a period of treatment stabilisation before primary care prescribing is appropriate.
The specialist teams will provide a minimum of 2 months supply of medication before transferring the continued prescribing to primary care.
A DEXA scan is required at 1 year of treatment, which will be performed by the specialist team.
For further information, refer to the NICE website.
- relugolix-estradiol-norethisterone for treating symptoms of endometriosis [NICE TA1057]
- linzagolix for treating symptoms of endometriosis [NICE TA1067]
- relugolix-estradiol-norethisterone acetate for treating moderate-to-severe symptoms of uterine fibroids [NICE TA832]
- linzagolix for treating moderate-to-severe symptoms of uterine fibroids [NICE TA996]
- relugolix-estradiol-norethisterone (relugolix combination therapy [CT]) and linzagolix are black triangle drugs▼: report all suspected adverse reactions via the Yellow Card scheme.
ScriptSwitch® messages have been enabled to support prescribers.
